ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

All Content

The FGFR inhibitor dovitinib showed modest efficacy in a phase II trial of patients with pretreated, advanced squamous cell lung cancer with FGFR1 amplification

A study covering 4 decades of patients with chronic myeloid leukemia in Sweden found dramatic improvements in life expectancy since the advent of tyrosine kinase inhibitor therapy.

Three single-nucleotide polymorphisms were identified that are significantly associated with OS in two separate cohorts of pediatric Ewing sarcoma patients.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses new regulations from the FDA that subject e-cigarettes and hookahs to some of the same regulations as tobacco products.

In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.

Researchers were able to molecularly classify endometrial cancers with distinct survival differences using a new classification tool called ProMisE that uses clinically applicable methods.

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.

The anti-CCR4 antibody mogamulizumab showed promising response rates compared to investigator’s choice in a randomized phase II trial of relapsed/refractory adult T-cell leukemia/lymphoma.

Similar survival outcomes were seen in lymphoma patients who underwent related donor haploidentical HCT and HLA-matched sibling donor transplant.

Most metastatic cancer patients are still receiving aggressive methods of treatment near the end of life, and palliative/supportive measures are significantly underutilized.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.